Tonix Pharmaceuticals (NASDAQ:TNXP) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a report released on Friday. The brokerage issued a sell rating on the stock.

Separately, Dawson James started coverage on Tonix Pharmaceuticals in a research note on Wednesday, February 28th. They set a buy rating and a $3.00 price target on the stock.

Tonix Pharmaceuticals Price Performance

NASDAQ:TNXP opened at $0.16 on Friday. The stock’s 50-day simple moving average is $0.29 and its 200 day simple moving average is $0.39. The company has a quick ratio of 1.81, a current ratio of 2.53 and a debt-to-equity ratio of 0.06. Tonix Pharmaceuticals has a twelve month low of $0.12 and a twelve month high of $3.31.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings results on Monday, April 1st. The company reported ($0.86) EPS for the quarter. The firm had revenue of $3.78 million during the quarter, compared to analysts’ expectations of $3.95 million. Equities analysts predict that Tonix Pharmaceuticals will post -3.71 earnings per share for the current fiscal year.

Institutional Trading of Tonix Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the company. UBS Group AG lifted its stake in shares of Tonix Pharmaceuticals by 18,868.5% in the fourth quarter. UBS Group AG now owns 67,528 shares of the company’s stock worth $26,000 after acquiring an additional 67,172 shares during the period. Two Sigma Investments LP lifted its stake in shares of Tonix Pharmaceuticals by 183.9% in the first quarter. Two Sigma Investments LP now owns 60,191 shares of the company’s stock worth $36,000 after acquiring an additional 38,991 shares during the period. Raymond James & Associates acquired a new position in shares of Tonix Pharmaceuticals in the fourth quarter worth approximately $65,000. JPMorgan Chase & Co. lifted its stake in shares of Tonix Pharmaceuticals by 36.9% in the first quarter. JPMorgan Chase & Co. now owns 285,321 shares of the company’s stock worth $66,000 after acquiring an additional 76,935 shares during the period. Finally, Virtu Financial LLC lifted its stake in shares of Tonix Pharmaceuticals by 44.8% in the fourth quarter. Virtu Financial LLC now owns 188,075 shares of the company’s stock worth $73,000 after acquiring an additional 58,184 shares during the period. 82.26% of the stock is owned by institutional investors and hedge funds.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.